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Abbreviations 
Abbreviation Abbreviation Description 
ABC Avidin-Biotin Complex 
APC Adenomatous polyposis coli gene 
APS Ammonium peroxodisulfate 
CLSM Confocal laser scanning microscopy 
COAD Colon adenocarcinomas 
CpG Cytosine phosphate guanidine 
CRC Colorectal cancer 
CSC Cancer stem cell 
Cy3 Cyanine 3 
DAB 3, 3-diaminobenzidine 
DAPI 4’, 6-diamidino-2-phenylindole 
DEPC Diethyl Pyrocarbonate 
DIG Digoxigenin 
DMEM Dulbecco's modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DOX Doxycycline 
dNTP Deoxynucleotides triphosphate 
E.coli Escherichia coli 
ECL Electrochemiluminescence 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EMT Epithelial mesenchymal transition 
FBS Fetal bovine serum 
FFPE Formalin-fixed paraffin-embedded 
FISH Fluorescence in situ hybridization 
FITC Fluorescein 
GDC Genomic data commons 
GFP Green fluorescent protein 
GO Gene Ontology 
GSEA Gene Set Enrichment Analysis 
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Abbreviation Abbreviation Description 
H&E Hematoxylin and eosin 
HBSS Hank's balanced salt solution 
HRP Horseradish peroxidase 
IEC Intestinal epithelial cell 
IHC Immunohistochemistry 
IPSC Induced pluripotent stem cell 
lncRNA Long non-coding RNA 
ISC Intestinal stem cell 
ISH In situ hybridization 
IVC Individually ventilated cages 
KEGG Kyoto Encyclopedia of Genes and Genomes 
MAPK Mitogen-activated protein kinase 
miRNA Micro RNA 
mRNA Messenger RNA 
Neo Neomycin 
NGS Next-generation sequencing 
ORF Open reading frame 
PAS Periodic acid–Schiff 
PBS Phosphate-buffered saline 
PFA Paraformaldehyde 
PI3K Phosphoinositide 3-kinase 
RTK Receptor tyrosine kinases 
RNA Ribonucleic acid 
SDS Sodium dodecyl sulfate 
SSC Saline-sodium citrate 
STR Short tandem repeat 
TBST Tris-buffered saline with 0.1% Tween 20 
TCGA The Cancer Genome Atlas 
TEMED Tetramethylethylenediamine 
UTR Untranslated region 
WB Western blotting 
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1. Introduction 
1.1 Cancer: a primer 
Cancer is a major health problem worldwide. Only in 2012, approximately 
14.1 million patients were diagnosed with and 8.2 million people died from 
cancer [1]. Tumorigenesis is a multistep process during which several 
oncogenes are activated and tumor-suppressor genes are inactivated by 
genetic or epigenetic mechanisms [2,3]. This mechanism was initially 
described for colorectal cancer (CRC) [4] (Figure 1). Oncogenes and tumor-
suppressor genes encode proteins and microRNAs that affect numerous 
cellular processes. Oncogenes are often mutated or highly expressed in 
cancer cells. Tumor-suppressor genes negatively regulate the cell cycle and 
promote apoptosis, thereby preventing the transformation of normal to cancer 
cells. MicroRNAs regulate gene expression by binding to target mRNAs, 
which blocks protein translation or causes degradation of the target mRNA. 
Tumor suppressive miRNAs suppress the expression of mRNAs, which 
encode oncogenic proteins. In case these miRNAs are down-regulated or 
inactivated the respective target oncogenes show elevated expression [5,6]. 
 
1. Introduction 
4 
 
 
Figure 1. 
The mutations occurring during multi-step progression in colon cancer. The top half 
represents progressive lesion formation with altered cellular properties. The bottom 
half shows key genes deregulated during colorectal cancer progression. 
(Figure taken from: Green JE, et al. Nature Reviews Cancer, 2005) [7] 
 
 
1.2 Colorectal cancer 
Among all different types of cancer, CRC is one of the leading causes of 
cancer death (Figure 2). In the United States alone 135,430 new cases and 
50,260 deaths from CRC are expected in 2017 [8]. CRC is a multistep 
process driven by mutational activation of several oncogenes and 
genetic/epigenetic inactivation of tumor suppressors [9] (Figure 1). The 
majority of CRCs originate from benign adenomas, which are caused by 
inactivating mutations in the adenomatous polyposis coli (APC) gene [10]. 
APC mutation leads to the constitutive activation of the Wnt/β-catenin 
pathway which results in the increased expression of β-catenin [11], a critical 
regulator of intestinal epithelial cell homeostasis [12]. During CRC progression 
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additional mutations in key oncogenes and tumor suppressor genes, such as 
p53 [4,13], are acquired. 
 
 
Figure 2. 
Ten leading estimated cancer deaths by sex, United States, 2017. Estimates are 
rounded to the nearest 10 and cases exclude basal cell and squamous cell skin 
cancers and in situ carcinoma except urinary bladder. 
(Figure taken from: Siegel RL, et al. CA: A Cancer Journal For Clinicians, 2017) [8] 
 
 
1.3 The p53 tumor suppressor 
The tumor suppressor protein p53 is a central regulator of the stress 
response and plays a crucial role in suppression of tumorigenesis [14]. p53 is 
induced by acute DNA damage or other cellular stresses that result in DNA 
damage, such as replication stress caused by oncogene activation. Activated 
p53 promotes cell cycle arrest, apoptosis and senescence (Figure 3). These 
effects of p53 activation contribute to the elimination of damaged cells, which 
would otherwise progress to tumors, thereby mediating suppression of 
tumorigenesis. p53 is inactivated in ca. 60% of CRCs [15]. Mutations in p53 
often increase the aggressiveness and malignancy of tumors and are 
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associated with poor patient prognosis. Although the p53 tumor suppressor 
has been extensively studied in the past 25 years, it is still unclear which and 
how its downstream targets mediate tumor suppression. Besides regulating 
the expression of mRNAs, p53 also controls the expression of non-coding 
RNAs, such as lncRNAs and microRNAs (miRNAs) [16,17], not only at the 
transcriptional level but also at the steps of processing and maturation [18]. 
Many tumor suppressive functions of p53 are thought to be mediated by p53-
induced miRNAs [19,16]. Among the p53-induced microRNA-encoding genes, 
miR-34a and miR-34b/c display the most consistent and pronounced 
induction after p53 activation which may explain why they were identified as 
one of the first p53-regulated miRNAs [20,21]. 
 
 
Figure 3. 
The classical view of p53 activation and response. In response to acute DNA 
damage signals and hyper-proliferative signals are the most well established 
molecular models for p53 activation. 
(Figure taken from: Bieging KT, et al. Nature Reviews Cancer, 2014) [22] 
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1.4 The miR-34 family 
miRNAs are a class of non-protein coding RNAs and with a length of ~22 
nucleotides. They play important roles in regulating their target mRNAs. The 
nucleotide positions 2 – 8 of the miRNA are called “seed region” and are 
partially complementary to a site in 3’-UTR of its target mRNAs, the so-called 
“seed-matching region”. The mature miRNA and associated proteins form a 
RNA-induced silencing complex (miRISC). After association with the seed-
matching region, miRNAs either lead to cleavage or to translational 
suppression of the respective target mRNAs (Figure 4) [23]. 
Among all miRNAs, miR-34a and miR-34b/c show the most marked 
induction by p53. The miR-34a gene is located on chromosome 1p36.22 and 
miR-34b/c genes are located on 11q23.1. The promoters of miR-34a and 
miR-34b/c contain several p53 responsive elements and p53 can directly bind 
to these elements and induce transcription. miR-34a and miR-34b/c 
presumably mediate tumor suppression by p53 via down-regulation of key-
regulators numerous cancer associated processes, such as cell proliferation 
and survival [20], EMT [24], metastasis [25] and stemness [26] (Figure 5). 
Interestingly, some of these targets form feedback loops with p53 and miR-
34s to regulate p53 functions [19]. For example, the oncogenic transcription 
factor c-Myc, which induces cell growth and proliferation, is directly repressed 
by miR-34a/b/c [27]. By repression of Sirt1, a deacetylase negatively 
regulating p53, miR-34a induces senescence [28]. Raver-Shapira et al. found 
that inhibition of miR-34a protects cells from this effect in wild-type p53 cells 
which suggests that miR-34a is, at least in part, required for p53-induced 
apoptosis [21]. 
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 Cancer stem cells (CSCs) account for cancer initiation, progression, and 
recurrence [29]. miR-34 levels are reduced in the CSC population of cancer 
cell lines [30,31] and re-expression of miR-34 in cancer cells can block tumor 
regeneration and metastasis [32]. miR-34a/b/c presumably function as cell-
fate determinants in colonic cancer stem cells (CCSC) by regulating Notch 
activity as it directly targets the Notch1 and Numb mRNAs [33,34]. 
Furthermore, miR-34a/b/c regulate the homeostasis of normal stem cells [35] 
and suppress the formation of induced pluripotent stem cells (IPSCs) [36].  
Consistent with a tumor suppressive role in tumorigenesis, down-
regulation of miR-34a/b/c expression has been observed in a variety of 
human cancers [16]. miR-34a/b/c expression was reported to be down-
regulated in CRC cell lines due to epigenetically silencing by CpG methylation 
[37]. In primary CRCs, 74% miR-34a and 99% miR-34b/c were methylated 
[38,39]. These findings suggest important roles of miR-34a/b/c as 
downstream effectors of p53 and potential tumor suppressors of CRC. In line 
with its tumor suppressive potential miR-34a mimetics are currently tested in 
the clinics for treatment of advanced cancer [40]. 
In mice, miR-34a is universally expressed and exhibits the highest levels 
of expression in the brain [41]. miR-34b/c is mainly expressed in the lung and 
almost undetectable in other tissues [41]. Surprisingly, opposed to p53-
deficient mice, miR-34a/b/c-deficient mice did not show spontaneous 
tumorigenesis [42]. However, miR-34a deficiency stimulated tumorigenesis 
when one allele of p53 was lost [43]. Besides, prostate epithelium specific 
inactivation of miR-34a/b/c and p53 resulted in an enlarged prostate stem cell 
compartment and the development of invasive adenocarcinomas and high 
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grade prostatic intraepithelial neoplasia [35]. Taken together, these findings 
indicate that the miR-34 family may have tumor-suppressor function by 
regulating aspects of stem cell biology. Additionally, the double knockout of 
both miR-34b/c and miR-449a/b/c, another member of the miR-34 family, 
resulted in oligo-astheno-teratozoospermia and infertility in mice [44]. 
Furthermore, deletion of miR-34a/b/c and miR-449a/b/c alleles results in 
postnatal mortality, infertility and respiratory dysfunction due to a defective 
motile ciliogenesis, which was, at least in part, mediated by de-repression of 
Cp110, a centriolar protein suppressing cilia assembly [45].  
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Figure 4. 
Genomic structure and regulation of miR-34 family members. Structure of miR-34a 
and miR-34b/c genomic loci. Green and red boxes represent exons and miRNA 
hairpins, respectively. 
(Figure taken from: Rokavec M, et al. Journal of Molecular Cell Biology, 2014) [19] 
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Figure 5. 
miR-34 regulates cancer-relevant pathways. The net effect of regulation by miR-34 
on each pathway/process is indicated by a green arrow (activation) or a red inhibitory 
symbol. 
(Figure modified from: Rokavec M, et al. Journal of Molecular Cell Biology, 2014) [19] 
 
 
1.5 The Wnt signaling pathway in colorectal cancer 
Wnt signaling is one of the essential pathways involved in embryonic 
development and stemness [46], and has been extensively studied and 
directly associated with tumorigenesis. The canonical WNT pathway is also 
known as WNT/β-catenin signaling. In the absence of WNT ligand, β-catenin 
is phosphorylated and degraded through a multi-protein complex consisting of 
the tumor-suppressor protein APC and glycogen synthase kinase 3β (GSK3β) 
[47]. When WNT ligands bind to Frizzled and LRP receptors at the cell 
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membrane and activate intracellular signaling, the phosphorylation and 
degradation of β-catenin is inhibited resulting in the nuclear translocation of β-
catenin. In the nucleus, β-catenin binds to the TCF/LEF complex and induces 
the transcription of WNT target genes [48] (Figure 6).  
The mechanisms of Wnt signaling in CRC cells are well studied and 
several related mouse models have been established, for example the 
ApcMin/+ mice [49]. ApcMin/+ mice inherit a mutant Apc allele, that results in a 
truncation of the APC protein at amino acid 850 [50], and spontaneously lose 
the wild-type Apc allele causing multiple benign adenomas mainly throughout 
the small intestine [51]. In humans, inherited germ-line mutations in one APC 
allele will lead to hundreds to thousands of adenomatous polyps mainly in the 
colon and rectum by the age of 25. The syndrome is known as familial 
adenomatous polyposis (FAP). Because of the large number of polyps, the 
patients will almost certainly develop CRCs in their forties to fifties [52,9]. To 
prevent the formation of CRCs part or all of their colon is surgical removed. As 
the early loss of APC is a hallmark of inherited and almost all sporadic CRCs, 
ApcMin/+ mice allow to study the influence of putative tumor suppressor genes 
on the initiation of intestinal tumorigenesis [53].  
Furthermore, β-catenin, the critical mediator of colon carcinogenesis [12] 
is a miR-34 direct target [54]. In our previous study, decreased miR-34a and 
increased β-catenin expression are associated with liver metastases of CRC 
[39]. Therefore, we generated mice ApcMin/+ mice carrying deletions of miR-
34a and miR-34b/c to determine their role in intestinal tumorigenesis. 
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Figure 6. 
Canonical WNT-β-catenin signaling. 
A. In the absence of WNT ligands, β-catenin is phosphorylated and degraded. The 
level of nuclear β-catenin is low. 
B. When WNT ligands bind to the receptor, β-catenin translocates to the nucleus and 
induces the transcription of WNT target genes. 
(Figure taken from: Staal FJ, et al. Nature Reviews Immunology, 2008) [55] 
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2. Aims of the study 
The present work had the following aims: 
1) Characterization of the biological function of miR-34a/b/c in the 
intestine using mice with deletions of their host genes. 
2) Evaluation of the tumor suppressive function of miR-34a/b/c in multiple 
intestinal neoplasia (ApcMin/+) mice. 
3) Comprehensive analysis of the effector network of miR-34a/b/c in 
intestinal adenoma development. 
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3. Materials 
3.1 Chemicals and reagents 
Chemical compound Supplier 
Ampicillin Sigma-Aldrich Co. LLC., USA 
Antibody Diluent with Background-
Reducing Components 
Agilent Technologies, USA 
APS (ammonium peroxodisulfate) 
Carl Roth GmbH + Co. KG, 
Germany 
B-27® Supplement (50X), minus 
vitamin A 
Thermo Fisher Scientific Inc., USA 
BD Matrigel™ Basement Membrane 
Matrix 
BD Bioscience, Germany 
Blocking Reagent 
Roche Diagnostics GmbH, 
Germany 
CHAPS (3-[(3-
Cholamidopropyl)dimethyl ammonio]-
1-propane sulphonate) 
Sigma-Aldrich Co. LLC., USA 
cOmplete Mini Protease Inhibitor 
Cocktail Tablets 
Roche Diagnostics GmbH, 
Germany 
DAPI (4’,6-diamidino-2-phenylindole) 
Carl Roth GmbH + Co. KG, 
Germany 
Diethyl pyrocarbonate Sigma-Aldrich Co. LLC., USA 
Distilled Water Thermo Fisher Scientific Inc., USA 
DMEM (Dulbecco's Modified Eagle 
Medium) 
Thermo Fisher Scientific Inc., USA 
DMSO (dimethyl-sulfoxide) 
Carl Roth GmbH + Co. KG, 
Germany 
dNTPs (deoxynucleotides 
triphosphate) 
Thermo Fisher Scientific Inc., USA 
Doxycycline hyclate Sigma-Aldrich Co. LLC., USA 
EGF Recombinant Mouse Protein Thermo Fisher Scientific Inc., USA 
Ethidium bromide 
Carl Roth GmbH + Co. KG, 
Germany 
Fast SYBR® Green Master Mix Thermo Fisher Scientific Inc., USA 
FBS (fetal bovine serum) Thermo Fisher Scientific Inc., USA 
Formamide Sigma-Aldrich Co. LLC., USA 
FuGENE® 6 Transfection Reagent Promega GmbH, Germany 
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Chemical compound Supplier 
Gene Ruler 100bp plus DNA ladder Thermo Fisher Scientific Inc., USA 
Gene Ruler Low Range DNA ladder Thermo Fisher Scientific Inc., USA 
GlutaMAX™ Supplement Thermo Fisher Scientific Inc., USA 
HBSS (Hank's Balanced Salt Solution) Thermo Fisher Scientific Inc., USA 
Heparin sodium Sigma-Aldrich Co. LLC., USA 
Hi-Di™ Formamide Thermo Fisher Scientific Inc., USA 
HiPerFect Transfection Reagent Qiagen GmbH, Germany 
Immobilon Western HRP Substrate Merck Millipore, Germany 
Immobilon®-P PVDF Membrane Merck Millipore, Germany 
LB agar (Lennox) 
Carl Roth GmbH + Co. KG, 
Germany 
LB medium (Luria/Miller) 
Carl Roth GmbH + Co. KG, 
Germany 
Methanol 
Carl Roth GmbH + Co. KG, 
Germany 
NaCl 
Carl Roth GmbH + Co. KG, 
Germany 
O’Gene Ruler 1kb DNA ladder Thermo Fisher Scientific Inc., USA 
Opti-MEM™ Reduced Serum Media Thermo Fisher Scientific Inc., USA 
PageRuler™ Prestained Protein 
Ladder 
Thermo Fisher Scientific Inc., USA 
Paraformaldehyde Merck Millipore, Germany 
Penicillin-Streptomycin Thermo Fisher Scientific Inc., USA 
peqGOLD Universal-Agarose VWR Peqlab, Germany 
POP-6™ Polymer for 3130/3130xl 
Genetic Analyzers 
Thermo Fisher Scientific Inc., USA 
ProLong® Gold antifade reagent Thermo Fisher Scientific Inc., USA 
RNA from yeast 
Roche Diagnostics GmbH, 
Germany 
Rotiphorese gel 30 (37,5:1) 
Carl Roth GmbH + Co. KG, 
Germany 
SDS (sodium dodecyl sulfate) 
Carl Roth GmbH + Co. KG, 
Germany 
Sigma-Aldrich Co. LLC., Sigma-Aldrich Co. LLC., USA 
Skim milk powder Sigma-Aldrich Co. LLC., USA 
Sodium citrate dihydrate Sigma-Aldrich Co. LLC., USA 
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Chemical compound Supplier 
Target Retrieval Solution, Citrate pH 6 Agilent Technologies, USA 
Temed (N,N,N',N'-
Tetramethylethylenediamine, 1,2-
Bis(dimethylamino)-ethane) 
Carl Roth GmbH + Co. KG, 
Germany 
Tris-base 
Carl Roth GmbH + Co. KG, 
Germany 
Triton® X 100 
Carl Roth GmbH + Co. KG, 
Germany 
Tween® 20 Sigma-Aldrich Co. LLC., USA 
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3.2 Enzymes 
Enzyme Supplier 
Collagenase Type IV Biochrom GmbH, Germany 
Dispase II Sigma-Aldrich Co. LLC., USA 
DNase I (RNase-Free) 
New England BioLabs GmbH, 
Germany 
HOT FIREPol® DNA Polymerase Solis BioDyne, Estonia 
Pfu DNA Polymerase Thermo Fisher Scientific Inc., USA 
Proteinase K Sigma-Aldrich Co. LLC., USA 
Restriction Endonuclease 
New England BioLabs GmbH, 
Germany 
T4 DNA Ligase Thermo Fisher Scientific Inc., USA 
Trypsin (10x) Thermo Fisher Scientific Inc., USA 
 
3.3 Kits 
Kit Supplier 
BCIP®/NBT Liquid Substrate 
System 
Sigma-Aldrich Co. LLC., USA 
BigDye® Terminator v1.1 Cycle 
Sequencing Kit 
Thermo Fisher Scientific Inc., USA 
DAB Substrate Kit Vector Laboratories, Inc., USA 
DIG Northern Starter Kit Roche Diagnostics GmbH, Germany 
Dual-Luciferase® Reporter 1000 
Assay Systems 
Promega GmbH, Germany 
DyeEx 2.0 Spin Kit Qiagen GmbH, Germany 
High Pure RNA Isolation Kit Roche Diagnostics GmbH, Germany 
ImmPRESS™ HRP Anti-Goat IgG 
(Peroxidase) Polymer Detection Kit 
Vector Laboratories, Inc., USA 
ImmPRESS™ HRP Anti-Rabbit IgG 
(Peroxidase) Polymer Detection Kit 
Vector Laboratories, Inc., USA 
Micro BCA™ Protein Assay Kit Thermo Fisher Scientific Inc., USA 
PureYield™ Plasmid Midiprep 
System 
Promega GmbH, Germany 
QIAprep Spin Miniprep Kit Qiagen GmbH, Germany 
QIAquick Gel Extraction Kit Qiagen GmbH, Germany 
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Kit Supplier 
QIAquick PCR Purification Kit Qiagen GmbH, Germany 
RNeasy Plus Mini Kit Qiagen GmbH, Germany 
VECTASTAIN Elite ABC HRP Kit Vector Laboratories, Inc., USA 
Verso cDNA Synthesis Kit Thermo Fisher Scientific Inc., USA 
 
3.4 Antibodies 
3.4.1 Primary antibodies 
Name Species Catalog No. Company Use Dilution Source 
Lysozyme Mouse LS-C138144 LSBio IHC 1:1000 Rabbit 
β-catenin Mouse ab32572 Abcam IHC 1:500 Rabbit 
Ki-67 Mouse #12202 CST IHC 1:400 Rabbit 
Cleaved-
Caspase-3 
Mouse #9664 CST IHC 1:500 Rabbit 
WASF1 
Human 
Mouse 
ab185546 Abcam WB 1:5000 Rabbit 
β-actin 
Human 
Mouse 
A2066 
Sigma-
Aldrich 
WB 1:1000 Rabbit 
Vimentin Mouse sc-7557 Santa Cruz IHC 1:100 Goat 
F4/80 Mouse MF48000 Invitrogen IHC 1:200 Rat 
CD45R Mouse 550286 BD IHC 1:100 Rat 
CD3 Mouse A 0452 DAKO IHC 1:100 Rabbit 
MUC1 Mouse ab15481 Abcam IHC 1:100 Rabbit 
IHC: Immunohistochemistry, WB: Western blot analysis 
 
3.4.2 Secondary antibodies 
Name Species 
Catalog 
No. 
Company Use Dilution Source 
Anti-Rabbit IgG-
Peroxidase 
Rabbit A0545 
Sigma-
Aldrich 
WB 1:10000 Goat 
Biotinylated  
Rabbit Anti-Rat  
Immunoglobulins 
Rat E 0468 DAKO IHC 1:300 Rabbit 
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Name Species 
Catalog 
No. 
Company Use Dilution Source 
Biotinylated  
Goat Anti-Rabbit  
Immunoglobulins 
Rabbit E 0432 DAKO IHC 1:500 Goat 
IHC: Immunohistochemistry, WB: Western blot analysis 
 
3.5 Vectors and oligonucleotides 
3.5.1 Vectors 
Name Insert Source 
pRTR-pri-miR-34a human pri-miR-34a [56] 
pGL3-control-MCS firefly luciferase 
Promega GmbH,  
Germany 
pGL3-Wasf1 mouse Wasf1 3’UTR this work 
pRL Renilla luciferase 
Promega GmbH,  
Germany 
pBluescript II SK(+)-
mOLMF4 
mouse Olfm4 Dr. Hans Clevers 
 
3.5.2 Oligonucleotides 
3.5.2.1  Oligonucleotides used for genotyping 
Name Sequence (5’ - 3’) Product 
miR_34a-Fwd ACCTTGCAGGTGCTCAGAAT Floxed 368bp 
Wildtype 510bp 
Knockout 623bp 
miR_34a-Rev-2 TGGAGCTAACGGAGTGTGTG 
miR_34a-Rev-4 CTACCCAAGCTCGACGAAGT 
miR_34a-Rev-8 TGCAGCACTTCTAGGGCAGT 
miR_34bc-A CTGCGCTTCTTTCTTCGATGTAGC Wildtype 177bp 
Knockout 244bp 
Floxed 335bp 
miR_34bc-B TGGCTTTAGGATCTCCATTTCAGC 
miR_34bc-D ACCTGGTTAAGTGGGCTGAGTTC
C 
APCmin-Mut TTCTGAGAAAGACAGAAGTTA Mutation 340bp 
Wildtype 600bp APCmin-Common TTCCACTTTGGCATAAGGC 
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Name Sequence (5’ - 3’) Product 
APCmin-Wt GCCATCCCTTCACGTTAG 
 
3.5.2.2  Oligonucleotides used for cloning 
Name Use Sequence (5’ - 3’) 
Mmu-c-AgeI-Wasf1-For Cloning 3’-UTR TGAACCGGTAACACGAGC
GGATTGAAAAC 
Mmu-c-PstI-Wasf1-Rev AAACTGCAGGGAAGGGG
TTCTGCTAAACG 
Wasf1-clone-seq-F1 
Sequencing Insert TATTGCAAGGCTGAATGC
AC 
Wasf1-clone-seq-R1 
TCCAGGGGGAAAAATTAA
GG 
 
3.5.2.3  Oligonucleotides used for qPCR 
        Name           Sequence (5’ - 3’) 
Mmu-q-Axl-For CTATCCAGGGGTGGAGAACA 
Mmu-q-Axl-Rev ACCGAGACATCAGGGCATAC 
Mmu-q-Pdgfra-For ACAGAGACTGAGCGCTGACA 
Mmu-q-Pdgfra-Rev ACTGGAACCTGTCTCGATGG 
Mmu-q-Pdgfrb-For AACCCCCTTACAGCTGTCCT 
Mmu-q-Pdgfrb-Rev TTGCCTTCTCTGCCACTCTT 
Mmu-q-Igf1-For TGGATGCTCTTCAGTTCGTG 
Mmu-q-Igf1-Rev GCAACACTCATCCACAATGC 
Mmu-q-Inhbb-For TCCGAGATCATCAGCTTTGCA 
Mmu-q-Inhbb-Rev TCTCCAGGACATAGGGGAGC 
Mmu-q-Wasf1-For CCACCCTGCCTGTAATCAGT 
Mmu-q-Wasf1-Rev GTTTTCAATCCGCTCGTGTT 
Mmu-q-Stc1-For ACAGCTGCCCAATCACTTCT 
Mmu-q-Stc1-Rev TCTCCATCAGGCTGTCTCTG 
Mmu-q-Fgfr1-For TTACCCAGTTGGGTCTGTCC 
Mmu-q-Fgfr1-Rev TTCTGTTTCCTGAGGGATGG 
Mmu-q-Actin-For CTAAGGCCAACCGTGAAAAG 
Mmu-q-Actin-Rev  ACCAGAGGCATACAGGGACA 
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        Name           Sequence (5’ - 3’) 
Mmu-q-Col4a2-For GTGCACAGCCAGGATACCTC 
Mmu-q-Col4a2-Rev CCCCCGTTACACTCGATAAA 
Mmu-q-Col6a2-For GCCTTCCCACTGACCTACAA 
Mmu-q-Col6a2-Rev TTGTTGATGGCGTGTACGAT 
Mmu-q-Cacna2d2-For GCCCCTAGTAGGACCACACA 
Mmu-q-Cacna2d2-Rev AGCCAGGAGAGACCAACTCA 
Mmu-q-Ctnnb1-For AGGGTGGGAATGGTTTTAGG 
Mmu-q-Ctnnb1-Rev GTGGCAAAAACATCAACGTG 
Mmu-q-Lef1-For ACAGGTCCCAGAATGACAGC 
Mmu-q-Lef1-Rev TGGAGACAGTCTGGGGTTTC 
Mmu-q-Lrp6-For TGATCGGAGAGGGTATGAGG 
Mmu-q-Lrp6-Rev AAGAACTCTTGGGCCTTGGT 
Mmu-q-Zeb1-For GCATGTGACCTGTGTGACAA 
Mmu-q-Zeb1-Rev GATAGGGCTTTTCCCCAGAG 
Mmu-q-Twist1-For CCCACCCCACTTTTTGACGA 
Mmu-q-Twist1-Rev GGGATGCCTTTCCTGTCAGT 
Mmu-q-Fn1-For AGTGCTTCATGCCGCTAGAT 
Mmu-q-Fn1-Rev GGGTGAAAGGACCACTCAAA 
Mmu-q-Ccnd1-For GCGTACCCTGACACCAATCTC 
Mmu-q-Ccnd1-Rev CTCCTCTTCGCACTTCTGCTC 
Mmu-q-Wnt1-For GCGTTCTGCACGAGTGTCTA 
Mmu-q-Wnt1-Rev GGTAGGGTGGGCAAACATCA 
Mmu-q-Wnt3-For CGGCTTTACAGAGGGGCTTT 
Mmu-q-Wnt3-Rev TAGCCCAGCCTGTTCTGTTG 
Mmu-q-Muc1-For GACATCTTTCCAACCCAGGA 
Mmu-q-Muc1-Rev GGGGTGACTTGCTCCTACAA 
Mmu-q-Tff3-For AATGTGCCCTGGTGCTTCAA 
Mmu-q-Tff3-Rev GATCGGGGATGCTTGCTACC 
Mmu-q-Retnlb-For CTGATAGTCCCAGGGAACGC 
Mmu-q-Retnlb-Rev GTCTGCCAGAAGACGTGACA 
Hsa-q-Wasf1-For TGATGCCAGGAGTGTGCTAC 
Hsa-q-Wasf1-Rev GCGTTCATGCTTAGCTTCCT 
Hsa-q-Actin-For TGACATTAAGGAGAAGCTGTGCTA 
Hsa-q-Actin-Rev  GAGTTGAAGGTAGTTTCGTGGATG 
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3.5.2.4  Oligonucleotides used for fluorescence in situ hybridization 
(FISH) 
Name                  Sequence (5’ - 3’) 
universal eubacteria 
probe (EUB338) [57] 
[FITC]-5’-GCTGCCTCCCGTAGGAGT-3’ 
negative control probe 
(NON338) [57] 
[Cy3]-5’-CGACGGAGGGCATCCTCA-3’ 
 
3.5.3 miRNA mimics 
miRNA mimics Supplier 
Pre-miR™ miRNA Precursor Negative 
Controls 
Thermo Fisher Scientific Inc., USA 
Pre-miR™ miRNA Precursor PM11030 
(hsa-miR-34a-5p) 
Thermo Fisher Scientific Inc., USA 
Pre-miR™ miRNA Precursor PM11039 
(hsa-miR-34c-5p) 
Thermo Fisher Scientific Inc., USA 
 
3.6 Buffers and solutions 
3.6.1 Buffers for animal genotyping 
Proteinase K buffer: 
 0.1 M Tris (pH 8.5) 
 0.2 M NaCl 
 5 mM EDTA (pH 8.0) 
 0.2% SDS 
„Vogelstein“ PCR buffer (10X) [58]: 
 166 mM NH4SO4 
 670 mM Tris (pH 8.8) 
 67 mM MgCl2 
 100 mM β-mercapto-ethanol 
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3.6.2 Buffers and media for cell and tumor organoid culture 
Cell culture medium: 
 90% DMEM medium 
 10% FBS 
 100 U/ml penicillin 
 100 μg/ml streptomycin 
Cell freezing medium: 
 40% DMEM medium 
 50% FBS 
 10% DMSO 
EDTA chelation buffer [59]: 
 2 mM EDTA 
 5.6 mM Na2HPO4 
 8.0 mM KH2PO4 
 96.2 mM NaCl 
 1.6 mM KCl 
 43.4 mM sucrose 
 54.9 mM D-sorbitol 
 0.5 mM DL-dithiothreitol 
Adenoma cell digestion buffer [60]: 
 2.5% FBS 
 100 U/ml penicillin 
 100 μg/ml streptomycin 
 200 U/ml Type IV collagenase 
 125 μg/ml Type II dispase 
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 in DMEM medium 
Tumor organoid culture medium [59]: 
 100 U/ml penicillin 
 100 μg/ml streptomycin 
 10 mmol/L HEPES 
 2 mM Glutamax 
 1x B27 supplement 
 50 ng/ml EGF 
 in Advanced DMEM/F12 
 
3.6.3 Buffers and solutions for Western blot analysis 
RIPA buffer: 
 1% NP40 
 0.5% Sodium deoxycholate 
 0.1% SDS 
 150 mM NaCl 
 50 mM TrisHCl (pH 8.0) 
Laemmli buffer (2X): 
 125 mM TrisHCl (pH 6.8) 
 4% SDS 
 20% glycerol 
 0.05% bromophenol blue 
 10% β-mercapto-ethanol 
Electrode buffer (Tris/glycine/SDS running buffer) (10X): 
 144.0 g glycine 
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 30.3 g Tris base 
 10.0 g SDS 
 H2O to 1000 ml 
Transfer buffer: 
 200 mM glycine 
 20% methanol 
 25 mM Tris base (pH 8.6) 
TBST (10X): 
 0.2 M Tris base 
 1.5 M NaCl 
 0.5% Tween 20 
 
3.6.4 Buffers and solutions for in situ hybridization 
PBS (10X): 
 1.37 M NaCl 
 27 mM KCl 
 100 mM Na2HPO4 
 18 mM KH2PO4 
 Adjust pH to 7.2 wih HCl 
SSC (5X): 
 0.75 M NaCl 
 0.075 M Sodium citrate 
Tris/NaCl buffer 
 0.1 M TrisCl (pH 7.5) 
 0.15 M NaCl 
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 0.1% Tween 20 
Blocking solution: 
 1% blocking powder 
 1X Tris/NaCl buffer 
Hybridization buffer: 
 50% formamide 
 5X SSC 
 2% blocking powder 
 0.05% CHAPS 
 5 mM EDTA 
 50 μg/ml heparin 
 1 μg/ml yeast RNA 
NTM buffer: 
 0.1 M TrisHCl (pH 9.5) 
 0.1 M NaCl 
 0.05 M MgCl2 
 
3.6.5 Buffers and solutions for Fluorescence in situ hybridization 
Hybridization buffer [61]: 
• 0.9 M NaCl 
• 20 mM Tris/HCl pH7.3 
• 0.01% SDS 
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3.7 Animals 
Strain Background Source 
miR-34afl/fl mice C57BL6/SV129 This work [62] 
miR-34b/cfl/fl mice C57BL6/SV129 
Dr. Alexander Nikitin (Cornell 
University) [35] 
Flp mice C57BL6 The Jackson Laboratory 
CMV-Cre mice C57BL6 The Jackson Laboratory 
ApcMin/+ mice C57BL6 
Dr. Marlon Schneider (Ludwig-
Maximilians-University of Munich) 
 
3.8 Laboratory equipment 
Device Supplier 
440CF Imaging System Eastman Kodak Company, USA 
Applied Biosystems® 3130 Genetic 
Analyzer 
Thermo Fisher Scientific Inc.,USA 
Applied Biosystems® GeneAmp 
PCR System 9700 
Thermo Fisher Scientific Inc.,USA 
AxioPlan 2 Microscope System Carl Zeiss Meditec AG, Germany 
Axiovert 25 Inverted Microscope Carl Zeiss Meditec AG, Germany 
Cell culture flasks, Multiwall plates 
and Conical Tubes 
Corning Incorporated, USA 
Eppendorf 5417C Centrifuge Eppendorf GmbH, Germany 
FluorChem FC2 Imaging System ProteinSimple, USA 
Forma™ Water-Jacketed CO2 
Incubator 
Thermo Fisher Scientific Inc.,USA 
Hemacytometer Thermo Fisher Scientific Inc.,USA 
Heraeus™ Fresco™ 
Microcentrifuge 
Thermo Fisher Scientific Inc.,USA 
Heraeus™ Megafuge 1.0 Centrifuge Thermo Fisher Scientific Inc.,USA 
Heraeus™ Pico™ Microcentrifuge Thermo Fisher Scientific Inc.,USA 
Herasafe™ KS, Class II Biological 
Safety Cabinet 
Thermo Fisher Scientific Inc.,USA 
HTU SONI-130 MiniFIER 
Homogenizer 
G. HEINEMANN Ultraschall- und 
Labortechnik, Germany 
LightCycler® 480 Instrument II Roche Molecular Systems Inc., USA 
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Device Supplier 
LSM 700 Laser Scanning Confocal 
Microscope 
Carl Zeiss Meditec AG, Germany 
Mastercycler™ pro PCR System Eppendorf GmbH, Germany 
Mini-PROTEAN® Electrophoresis 
System 
Bio-Rad Laboratories, Inc., Germany 
NanoDrop® ND-1000 
Spectrophotometer 
Thermo Fisher Scientific Inc.,USA 
Orion II Microplate Lumimometer 
Berthold Detection Systems GmbH, 
Germany 
Varioskan™ Flash Multimode 
Reader 
Thermo Fisher Scientific Inc.,USA 
Waterbath WNB 45 
Memmert GmbH + Co. KG, 
Germany 
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4. Methods 
4.1 Propagation of bacteria 
4.1.1 Inoculation and cultivation of bacteria 
The E.coli XL1-blue strain was used for cloning and production of 
plasmids. The bacteria were propagated in liquid culture (LB-medium, shaking 
at 225 rpm) or on solid culture (LB-agar) at 37°C overnight. An ampicillin 
selection (100 µg/ml ampicillin) was used to select the bacteria carrying 
plasmids with ampicillin resistance gene. All vectors used in this work 
contained an ampicillin resistance cassette. 
 
4.1.2 Transformation 
One hundred microliter aliquot of E.coli XL1-blue cells were thawed on ice 
and then added 100 ng of plasmid DNA to the cells. After 30 minutes stand on 
ice, cells were incubated at 42°C for 60 seconds and put back on ice for 5 
minutes. Then 900 µl LB-medium was added and cells were incubated at 
37°C for 1 hour. To increase colony number, cells were centrifuged at 2000 
rpm for 5 minutes and removed the supernatant. Finally, the remaining cells 
were resuspended and spread onto a pre-warmed (37°C) culture plate with 
LB-agar containing ampicillin at 37°C overnight. 
 
4.1.3 Purification of plasmid DNA from bacteria 
Bacterial cell was cultured in either 5 ml (small amount) or 150 ml (big 
amount) LB-medium with ampicillin overnight at 37°C (shaking at 225 rpm). 
For the small amount plasmid DNA isolation, QIAprep Spin Miniprep Kit 
(QIAGEN) was used according to the handbook from the manufacturer. For 
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the big amount plasmid preparation, PureYield Plasmid Midiprep System 
(Promega) was used by following the instruction of the manufacturer.  
 
4.2 Mammalian cell culture 
4.2.1 Propagation of mammalian cell lines 
H1299 lung cancer cells used for 3’-UTR reporter assays were from own 
stocks and their negativity for p53 were validated. SW620 CRC cells used for 
ectopic pri-miR-34a expression were from own stocks and authenticated by 
STR analysis in 2014 (Eurofins Genomics, Ebersberg, Germany). H1299 and 
SW620 cancer cell lines were kept in Dulbecco's modified Eagle’s medium 
(DMEM) with 10% fetal calf serum (Invitrogen), 100 U/ml penicillin and 100 
μg/ml streptomycin at a 37°C and 5% CO2 humid incubator. All cell lines were 
passaged every 3 days. 
 
4.2.2 Transfection of plasmids 
For the transfection of plasmid vectors, SW620 cells were trypsinized and 
seeded into a 12-well plate at 2 × 105 cells per well with 900 µl Opti-MEM 
medium. 3 µl FuGENE 6 transfection reagent (Promega) was diluted in 100 µl 
Opti-MEM medium and incubated at room temperature for 5 minutes. 2 µg of 
plasmid DNA was added to the FuGENE 6/medium, mixed immediately and 
incubated for 25 minutes. The transfection reagent mix was added to the cells 
drop-wise, and then returns cells to the incubator for 24 - 48 hours before 
assay. 
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4.2.3 Conditional expression in cell pools 
SW620 cells were transfected with episomal pRTR-pri-miR-34a [24] 
expression plasmids. After 24 hours cell pools were selected by addition of 
Puromycin (2 μg/ml) for 10 days. GFP expression was evaluated by 
fluorescence microscopy 48 hours after addition of 100 ng/ml Doxycycline 
(DOX) to the cell pools. 
 
4.2.4 Cryo-preservation of mammalian cells 
Cells were trypsinized and resuspended in complete medium. After 
determination of the total number of cells, cell suspension was centrifuged at 
200 g for 5 minutes. Supernatant was removed and the cells were 
resuspended in cold freezing medium. The cell suspension was then 
dispensed into cryogenic storage vials. The aliquots were placed in an 
isopropanol chamber and stored at -80°C overnight, then transferred to liquid 
nitrogen in the second day. 
 
4.3 Generation of mice 
4.3.1 Generation of miR-34a/b/c-/- mice 
The generation of miR-34a-/- mice with a C57BL6/SV129 back-ground has 
been described previously [62]. miR-34b/cfl/fl mice were kindly provided by Dr. 
Alexander Nikitin (Cornell University, New York, USA) [35]. In brief, gene-
specific deletions were generated by using homologous recombination with a 
vector containing miR-34a or miR-34b/c sequences flanked by loxP sites and 
an intronic Neomycin resistance (Neo) cassette flanked frt sites individually 
[62]. The Neo cassette was removed by crossing with flp-mice and germ-line 
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miR-34a or miR-34b/c knock-out mice were generated by crossing with CMV-
Cre mice. miR-34a/b/c-/- compound mice were generated by crossing miR-
34a-/- and miR-34b/c-/-.  
 
4.3.2 Generation of miR-34a/b/c-/-; ApcMin/+ mice 
miR-34a-/-, miR-34b/c-/-, miR-34a-/-; miR-34b/c-/- and miR-34a+/+; miR-
34bc+/+ mice were crossed with ApcMin/+ mice to obtain mice with the following 
genotypes: miR-34a-/-; ApcMin/+, miR-34b/c-/-; ApcMin/+, miR-34a/b/c-/-; ApcMin/+, 
and miR-34a/b/c+/+ ApcMin/+. Mice were housed in individually ventilated cages 
(IVC). Animal studies were approved by the Government of Upper Bavaria, 
Germany (AZ 55.2-1-54-2532-4-2014). 
 
4.4 Tumor organoid formation assay 
4.4.1 Isolation of tumor cells from murine intestinal adenomas 
Eighteen weeks old wild-type ApcMin/+ and miR-34a/b/c-/-; ApcMin/+ mice 
were sacrificed and intestine was collected and flushed with cold sterile PBS. 
Longitudinal opened intestinal fragments were incubated in EDTA chelation 
buffer on ice for 60 minutes. After incubation, the intestinal fragments were 
washed with cold chelation buffer two times and with cold sterile PBS two 
more times. Adenomas were then isolated from intestine and cut into 1 - 2 
mm3 fractions. Next, the adenoma fractions were incubated in adenoma cell 
digestion buffer for 2 hours at 37°C. Allow the adenoma fractions to settle 
down for 1 minute at normal gravity. The supernatant was collected in a 15 ml 
falcon tube, pelleted by centrifuging at 200 g for 5 minutes and washed once 
with cold sterile PBS. 
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4.4.2 Tumor organoid culture 
Adenoma cells were resuspended in sterile PBS, and counted using a 
hemocytometer. Single adenoma cells were centrifuged at 200 g for 5 minutes, 
embedded in 4 mg/ml cold Matrigel on ice and seeded in 24-well plates at 
15,000 cells per 50 µl Matrigel per well. The plates were then incubated at 
37°C for 20 minutes until the Matrigel was fully polymerized and 500 µl tumor 
organoid culture medium containing 50 ng/ml mouse EGF was added per well. 
The plates were kept at a 37°C and 5% CO2 humid incubator. 
 
4.4.3 Cryo-preservation of tumor organoids 
Medium was removed and 1 ml of ice-cold sterile PBS was added to each 
well, tumor organoids were disrupted by a P1000 sterile pipette with tips cut 
off and transferred to a 1.5 ml microcentrifuge tube. The supernatant was 
passed through a 27-gauge syringe 5 times, and then centrifuged 200 g for 5 
minutes at 4°C. Resuspend the pellet in freezing medium, the tumor organoid 
suspension was then dispensed into cryogenic storage vials. The freezing 
containers were placed in an isopropanol chamber and stored at -80°C for 24 
hours, then transferred to liquid nitrogen. 
 
4.5 Isolation of DNA from mouse tails  
Tail biopsies were obtained form 3 weeks old mice and placed to a 1.5 ml 
microcentrifuge tube. 300 µl Proteinase K buffer and 3 µl Proteinase K (10 
mg/ml) were added to each tail sample tube. The microcentrifuge tubes were 
incubated at 55°C overnight and then heated at 95°C for 10 minutes to 
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inactivate the Proteinase K. After centrifugation at 13,000 g for 5 minutes, the 
supernatant which containing mouse DNA was directly used to perform the 
genotyping PCR. 
 
4.6 PCR methods 
4.6.1 Genotyping PCR 
The genotyping PCR method for each gene was as followed: 
ApcMin/+ genotyping: 
Mastermix components (µl) Thermocycling conditions 
Component Vol. 
Vogelstein PCR buffer (10X): 2.5 
Tween 20 0.5 
10 mM dNTPs 1.0 
10 µM Mut Primer 1.0 
10 µM Common Primer 1.0 
10 µM Wt Primer 0.5 
Hot Firepol Taq DNA Polymerase 0.5 
Nuclease-free water 16.0 
Genomic DNA 2.0 
Total 25.0 
 
Step Temp Time 
Initial 95°C 15 min 
37 
Cycles 
95°C 
59°C 
72°C 
30 sec 
30 sec 
40 sec 
Final 72°C 3 min 
Hold 4°C  
 
 
miR-34a genotyping: 
Mastermix components (µl) Thermocycling conditions 
Component Vol. 
Vogelstein PCR buffer (10X): 2.5 
Tween 20 0.5 
10 mM dNTPs 1.0 
10 µM 34a-Fwd Primer 2.0 
10 µM 34a-Rev-2 Primer 1.0 
10 µM 34a-Rev-4 Primer 1.5 
10 µM 34a-Rev-8 Primer 0.5 
Hot Firepol Taq DNA Polymerase 0.5 
Step Temp Time 
Initial 95°C 15 min 
37 
Cycles 
95°C 
65°C 
72°C 
30 sec 
30 sec 
30 sec 
Final 72°C 3 min 
Hold 4°C  
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Nuclease-free water 13.5 
Genomic DNA 2.0 
Total 25.0 
 
 
miR-34bc genotyping: 
Mastermix components (µl) Thermocycling conditions 
Component Vol. 
Vogelstein PCR buffer (10X): 2.0 
Tween 20 0.5 
10 mM dNTPs 0.5 
10 µM 34bc-A Primer 1.0 
10 µM 34bc-B Primer 1.0 
10 µM 34bc-D Primer 1.0 
Hot Firepol Taq DNA Polymerase 0.5 
Nuclease-free water 11.5 
Genomic DNA 2.0 
Total 20.0 
 
Step Temp Time 
Initial 95°C 15 min 
37 
Cycles 
95°C 
59°C 
72°C 
30 sec 
30 sec 
45 sec 
Final 72°C 3 min 
Hold 4°C  
 
 
All genotyping primers are listed in chapter 3.5.2.1 
 
4.6.2 Cloning of the Wasf1 3’-UTR 
The 3’-UTR of Wasf1 was PCR amplified from genomic DNA isolated 
form mouse tissue. The PCR product was inserted into pGL3-control-MCS 
vector (Promega) downstream of a firefly luciferase ORF, and verified by 
sequencing. All primers that were used for cloning are listed in chapter 3.5.2.2. 
 
4.7 Isolation of RNA and reverse transcription 
4.7.1 Isolation of RNA 
High Pure RNA Isolation Kit (Roche) was used to isolate cultured 
mammalian cells. At least 1 × 106 cells were harvested for each sample, the 
cells were resuspended in PBS and followed the instruction of the 
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manufacturer. For the isolation of mice adenoma samples, a maximum 
amount of 20 mg fresh or frozen adenoma tissue was collected and added 
into Buffer RLT Plus (QIAGEN). Adenoma tissue was disrupted by a 
motorized homogenizer, and then the lysate was proceeded with RNeasy 
Plus Mini Kit (QIAGEN) with an on-column DNase I digestion according to the 
handbook from the manufacturer. The amount and quality of the isolated RNA 
was measured by NanoDrop spectrophotometer (Thermo Fisher Scientific). 
 
4.7.2 Reverse transcription 
Verso cDNA kit (Thermo Fisher Scientific) was used for cDNA synthesis 
according the instruction of the manufacturer.1 µg of total RNA and anchored 
Oligo-dT primer were used for reverse transcript reaction.   
 
4.8 Quantitative real-time PCR (qPCR) 
For analysis of mRNA expression levels, a LightCycler 480 Instrument II 
system (Roche) was used. qPCR reactions were conducted by using Fast 
SYBR Green Master Mix (Thermo Fisher Scientific). Relative gene expression 
was determined using the 2-ΔΔCt method [63]. The individual mRNA levels 
were normalized to β-actin. All qPCR primers are listed in chapter 3.5.2.3. 
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4.9 Protein isolation and Western blot analysis 
4.9.1 Protein isolation 
4.9.1.1  Protein isolation from mammalian cells 
Mammalian cells were cultured in general condition mentioned in chapter 
4.2. Before harvest, cells were washed with cold PBS for two times, and then 
lysed in cold RIPA buffer with cOmplete Mini Protease Inhibitor (Roche) 
added. Lysates were sonicated and centrifuged at 16,000 g, 4°C for 15 
minutes. The supernatant was collected to a new microcentrifuge tube and 
stored at -80°C for future use. 
 
4.9.1.2  Protein isolation from murine adenomas 
18 weeks old wild-type ApcMin/+ and miR-34a/b/c-/-; ApcMin/+ mice were 
sacrificed and intestine was collected and flushed with cold sterile PBS. 
Adenomas were then isolated from intestine and cut into 1 - 2 mm3 fractions. 
10 volumes of cold RIPA buffer with protease inhibitor were added to the 
adenoma fractions, and then adenoma tissue was disrupted by a motorized 
homogenizer. Lysates were sonicated and centrifuged at 16,000 g, 4°C for 15 
minutes. The supernatant was transferred to a new microcentrifuge tube and 
stored at a -80°C freezer. 
 
4.9.2 Western blot analysis 
4.9.2.1  Quantification of total protein 
Micro BCA Protein Assay Kit (Thermo Fisher Scientific) was used to 
determine the protein concentration of the protein samples. Varioskan Flash 
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Multimode Reader (Thermo Fisher Scientific) was used to measure the 
absorbance of each sample and calculate the concentration.  
 
4.9.2.2  Western blotting assay 
30-60 μg whole lysate proteins were supplemented with 2X Laemmli 
buffer and heated at 99°C for 5 minutes to denature proteins. The protein 
lysates were then loaded onto a 7.5% - 12% SDS-polyacrylamide gel with 
PageRuler Prestained Protein Ladder (Thermo Fisher Scientific). Protein 
electrophoresis was performed by using Mini-PROTEAN Tetra Cell (Bio-Rad) 
at a voltage of 60 – 120 with electrode (running) buffer. Then the proteins 
were transferred to an Immobilon-P PVDF Membrane (Merck Millipore) by 
using Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) at 100 V, 
constant 350 mA with cold transfer buffer. Non-specific binding of the 
membrane was blocked by incubated in 5% skim milk/TBST buffer for 30 
minutes. Then the membrane was transferred into TBST with primary 
antibodies diluted and incubated at 4°C overnight. Thereafter, the membrane 
was washed by TBST and incubated with secondary antibodies (HRP 
conjugated) at room temperature for 1 hour. For the detection, Immobilon 
Western HRP Substrate (ECL) (Merck Millipore) was applied to the 
membrane and 440CF Imaging System (KODAK) was used to detect 
chemiluminescent of the protein. All antibodies used are listed in chapter 3.4. 
 
4.10 Luciferase assay 
H1299 cells were trypsinized and seeded in a 12-well plate with 3 × 104 
cells/well and transfected with 100 ng of pGL3-Wasf1 plasmid, 20 ng of 
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Renilla reporter plasmid for normalization, and 25 nM miR-34a or miR-34c 
pre-miRNAs or a negative control oligonucleotide (Ambion) by using 
HiPerFect Transfection Reagent (Qiagen). 48 hours later luciferase assays 
were performed with the Dual-Luciferase Reporter 1000 Assay System 
(Promega). Fluorescence intensities were measured with an Orion II 
Microplate Luminometer (Titertek-Berthold). 
 
4.11 FFPE sample preparation 
18 weeks old mice were sacrificed and intestine was collected and 
flushed with cold PBS. The intestine was then opened longitudinally, 
photographed and rolled up as a “Swiss roll” and placed into at least 10 
volumes of 4% buffered formaldehyde. Then the sample cassettes were 
incubated at 4°C overnight. Dehydration, clearing, and wax infiltration were 
done by an automated tissue processor. Finally, the tissues were embedded 
in paraffin. 
 
4.12 Histologic analysis 
For each FFPE sample, 3 μm paraffin sections were cut for subsequent 
immunohistochemistry analysis. H&E staining and periodic acid–Schiff (PAS) 
staining were performed by an automated slide staining system according to 
standard protocols. Tumors from ApcMin/+ mice were classified as adenomas 
with either low- or high-grade dysplasia, based on nuclear-cytoplasmic ratio, 
nucleus location, prominence of nucleoli, gland architecture, amount of 
interglandular stroma, and the presence of mucus secretion. 
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4.13 Immunohistochemistry 
Paraffin sections were de-paraffinized and rehydrated through xylene and 
graded alcohol series according to standard protocol. Antigen unmasking was 
performed by immersing tissue sections into pre-heated Citrate Target 
Retrieval Solution (Agilent Technologies) and a 30 minutes heat-induced 
target retrieval procedure was carried out. After the tissue sections cooled 
down to the room temperature, 3% hydrogen peroxide was applied to the 
sections for 10 minutes to deactivate endogenous peroxidase activities. Then 
washed the sections with PBS and incubated for 30 minutes with blocking 
serum or 3% BSA solution. Blocking solution was removed, 100 µl primary 
antibody diluted in Antibody Diluent with Background-Reducing Components 
(Agilent Technologies) was added to each section and incubated at 4°C 
overnight. After washed with PBS, the sections were then incubated with 
diluted biotinylated secondary antibody for 1 hour. The signal amplification 
was performed by using VECTASTAIN Elite ABC HRP Kit (Vector 
Laboratories) and the signal was detected by using DAB Substrate Kit (Vector 
Laboratories). All antibodies used are listed in chapter 3.4. 
 
4.14 Scoring of immunohistochemical signals 
4.14.1 H-score 
For quantification of MUC1 expression the H-score was applied to ≥ 40 
tumors per genotype [64]. Each tumor was given an intensity value (I) from 0 
to 3 (0, no staining; 1, weak staining; 2, moderate staining; 3, strong staining) 
and the percentage (Pi) of the tumor area positive for the respective intensity 
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was recorded from 0 to 100%. The H-score was calculated as: H-score = Σ (Pi 
× I) (final range from 0 to 300).  
 
4.14.2 Computerized scoring 
For quantification of Vimentin positive area, Image-Pro Plus 6.0 software 
was used [65]. Section pictures were converted from the RGB color mode to 
the HSI (Hue-Saturation-Intensity) color mode. The HSI threshold parameters 
were set to H: 0 - 30; S: 0 - 255; I: 0 - 230 and the area inside this color 
ranges was counted as positive area. 
 
4.15 in situ hybridization 
4.15.1 in situ hybridization 
For detection of intestinal stem cells an Olfm4-specific, DIG-labeled RNA 
probe was generated using a murine Olfm4 vector in combination with a DIG 
Northern Starter Kit (Roche). Paraffin sections were de-paraffinized and 
rehydrated through xylene, graded ethanol series (100%, 95% and 70%), 
DEPC-treated dH2O and DEPC-treated PBS. The sections were then post 
fixed in 4% PFA-PBS for 10 minutes. After post-fixation, sections were 
incubated in 0.1% active DEPC-PBS for 30 minutes and equilibrated in 5X 
SSC. Thereafter, the sections were pre-hybridized in hybridization buffer at 
65°C for 2 hours. Removed hybridization buffer and replaced with new 
hybridization buffer containing 500 gm/ml of digoxigenin-labeled Olfm4 probe. 
The sections were hybridized at 65°C for 48 hours, and then rinsed in 2X SSC 
for 30 minutes at room temperature, 2X SSC for 1 hour at 60°C, 0.1X SSC for 
1 hour at 60°C and equilibrated in Tris/NaCl buffer for 5 minutes. Blocking 
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solution were applied to the sections and incubated for 30 minutes. Alkaline 
phosphatase conjugated anti-digoxigenin antibody (Roche) was diluted in 
blocking solution (1:1000). Blocking solution was removed, replaced with 
antibody solution and incubated the sections at 4°C overnight. After 
incubation, the slides were washed with Tris/NaCl buffer and NTM buffer. 
Color development was performed with BCIP/NBT Liquid Substrate System 
(Sigma-Aldrich) at room temperature for 48 – 72 hours. 
 
4.15.2 Fluorescence in situ hybridization 
Fresh paraffin sections were de-paraffinized and rehydrated to DEPC-
treated dH2O as described above. To visualize intestinal bacteria by FISH, 5’-
FITC-labeled universal eubacteria probe (EUB338) and 5’-Cy3-labeled 
negative control probe (NON338) were employed. The probes were 
synthesized (Metabion), diluted in per-warmed hybridization buffer to a final 
concentration of 1 ng/µl and added to the sections. The slides were incubated 
at 50°C overnight. After incubation, tissue sections were washed in pre-
warmed hybridization buffer, rinsed in dH2O and mounted with ProLong Gold 
antifade reagent (Thermo Fisher Scientific). 
 
4.16 Confocal laser scanning microscopy (CLSM)  
Fluorescence pictures were taken by using a LSM 700 Laser Scanning 
Confocal Microscope with ZEN 2009 software and Plan-Apochromat 20X/0.8 
M27 objective. For detection of DIPA signal, the following parameters were 
set up: laser 405 nm 2.0%; pinhole 33 µm; master gain 565; digital gain 1.20; 
digital offset 150; pixel dwell 101 µs. For FITC signal, laser 488 nm 2.0%; 
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pinhole 33 µm; master gain 1060; digital gain 1.20; digital offset 140; pixel 
dwell 101 µs. For Cy3 signal, laser 555 nm 2.0%; pinhole 33 µm; master gain 
740; digital gain 1.20; digital offset 150; pixel dwell 101 µs.  
 
4.17 Sequencing 
4.17.1 Sanger sequencing 
To verify the sequence of cloned 3’-UTR of Wasf1, Sanger sequencing 
was performed by Applied Biosystems 3130 Genetic Analyzer. BigDye 
Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific) was used to 
perform fluorescence-based cycle sequencing reactions. The components 
and cycling conditions were as followed: 
Reaction mixtures (µl) Thermocycling conditions 
Component Vol. 
Ready Reaction Premix 2.5X 4.0 
BigDye Sequencing Buffer 5X 2.0 
Primer 3.2 pmol 1.0 
Plasmid 1µg 1.0 
dH2O 2.0 
Total 10.0 
 
Step Temp Time 
Initial 96°C 1 min 
15 
Cycles 
96°C 
60°C 
10 sec 
90 sec 
Hold 4°C  
 
 
DyeEx 2.0 Spin Kit (Qiagen) was used to purify the extension products 
according to the instruction of the manufacturer. Purified products were 
diluted in Hi-Di Formamide (Thermo Fisher Scientific) and loaded onto 
Genetic Analyzer for electrophoresis with POP-6 polymer (Thermo Fisher 
Scientific). Data was collected with Foundation Data Collection Software v3.0 
and evaluated with DNAstar v7.1. 
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4.17.2 Next-Generation Sequencing (NGS) 
Total RNA from ApcMin/+ mice and miR-34a/b/c-/-; ApcMin/+ mice adenomas 
were isolated. 3 RNA samples per genotype were used for Next-Generation 
Sequencing and each tumor RNA sample represented a pool of 3 tumors 
isolated from the same mouse. Random primed cDNA libraries were 
constructed and sequenced using the HiSeq2500 (Illumina) platform by GATC 
(Konstanz, Germany). Each sample was covered by at least 35 million single 
reads of 50 bp length. Data were normalized in R with the RUVSeq [66] 
module, differential expression analysis was performed using Chipster 
software 3.7 (http://chipster.csc.fi/) [67]. The overlap of DEseq2 and edgeR 
results were considered to represent the most differentially expression genes. 
Gene Ontology (GO) and KEGG pathway analysis was performed with DAVID 
Bioinformatics Resources (https://david-d.ncifcrf.gov/) [68]. Gene Set 
Enrichment Analysis (GSEA) was performed using the GSEA software v2.2.2 
(http://software.broadinstitute.org/gsea/) [69]. miR-34a/b/c targets were 
predicted with TargetScan 6.2 (http://www.targetscan.org/) [70]. Expression 
data was deposited in the Gene Expression Omnibus website (Accession No. 
GSE84138). 
 
4.18 TCGA-COAD database analysis 
The Cancer Genome Atlas (TCGA) [71] gene expression data and follow-
up information of colon adenocarcinomas (COAD) were downloaded from 
NCI's Genomic Data Commons website (GDC; https://gdc.cancer.gov/) [72]. 
Log2(Normalized RSEM count + 1) was used to determine the expression of 
relevant mRNAs. The “normalized RSEM” was already normalized to the 
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library size and was a more accurate representation of the transcript 
abundances when compared to the “raw count” [73]. Clinical outcome data 
were divided into high, intermediate, and low expression groups according to 
the expression value of individual genes. 
 
4.19 Statistical analysis 
A two-tailed Student t test was used to compare continuous variables. 
Categorical variables were compared using the χ2 test or Fisher's exact test. 
Kaplan-Meier calculations were used to display the overall survival time and 
the results were compared with a log-rank test. The Sidak method was used 
to adjusted P values when multiple comparisons were performed. P values 
less than 0.05 were considered significant and indicated by asterisks (*P < 
0.05, **P < 0.01, or ***P < 0.0001). Univariate, age/gender/tumor grade-
adjusted hazard ratios and 95% confidence intervals (CIs) were estimated 
with a Cox’s proportional hazard model. Prism 6 (GraphPad software) or 
SPSS (IBM) programs were used for calculations.  
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5. Results 
5.1 miR-34a/b/c deletion modulates the architecture of the small 
intestine in mice  
Mice carrying deletions of the miR-34a or miR-34b/c loci and 
combinations of these were generated. Genotypes were identified by using 
PCR and agarose gel electrophoresis. The resulting genotypes were obtained 
in the expected Mendelian ratios. Deletion of miR-34a, miR-34b/c or miR-
34a/b/c in the germ-line did not significantly influence the lifespan of mice 
(Figure 7).  
 
 
 
However, we observed a gender-independent increase in the width and 
depth of crypts of the small intestine in miR-34a/b/c-deficient mice which 
presumably caused the minor increase in the total length of the small intestine 
(Figure 8).  
 
Figure 7. 
Kaplan-Meier survival analysis of mice with the indicated genotypes. Results were 
compared with a log-rank test. *** P < 0.001. 
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Notably, the numbers of Paneth cells per crypt and Goblet cells per villus 
were significantly increased in female and male miR-34a/b/c-deficient mice 
(Figure 9). In addition, the frequency of stem cells at the crypt base was 
significantly increased in miR-34a/b/c-deficient mice as determined by 
detection of the stem cell marker Olfm4 using in situ hybridization (Figure 10). 
 
Figure 8. 
Determination of the width (left graph) and depth (middle graph) of small intestinal 
crypts. At least 200 crypts in the jejunum from 18 weeks old mice were analyzed. 
The length (right graph) of the small intestine was determined in mice with the 
indicated genotypes (n ≥ 3 mice per gender). ** P < 0.01, *** P < 0.001 (Student's t-
test). 
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A  
 
 
B  
 
 
Figure 9. 
After PAS staining Paneth cell number per crypt (A) and Goblet cell number per 
villus (B) were evaluated in ≥ 50 crypts and ≥ 50 villi per mouse, respectively (n ≥ 3 
mice per gender). Scale bar: 25 μm. Results are presented as mean ± SEM. *** P < 
0.001 (Student's t-test). 
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In order to determine, whether inactivation of miR-34 genes affects 
intestinal tumor formation, we generated ApcMin/+ mice with deletions of miR-
34a, miR-34b/c or miR-34a/b/c. Genotype was identified by using PCR and 
agarose gel electrophoresis. In ApcMin/+ mice deficiency for miR-34a/b/c also 
resulted in an increase of the number of Paneth (Figure 11), Goblet and 
Olmf4-positive cells (Figure 12) per crypt in untransformed tissue of the small 
intestine.  
 
Figure 10. 
Representative pictures of in situ hybridization of Olfm4 positive cells in the crypts 
from indicated genotypes. At least 50 crypts per mouse were counted (n ≥ 3 mice 
per gender). Scale bar: 10 μm. Results are presented as mean ± SEM. *** P < 0.001 
(Student's t-test). 
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A  
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Figure 11. 
A. Paneth cell number per crypt after PAS staining was evaluated in ≥ 50 crypts per 
mouse (n ≥ 5 mice per gender). Scale bar: 25 μm. 
B. Detection of Lysozyme expression in Paneth cells. Scale bar: 25 μm.  
Results are presented as mean ± SEM. *** P < 0.001 (Student's t-test). 
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Similarly, the width and depth of the crypts were increased significantly in 
miR-34a/b/c-deficient ApcMin/+ mice, but the minor increased length of the 
small intestine was not statistically significant (Figure 13). Again, these 
A  
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Figure 12. 
A. Goblet cell number per villus was evaluated by PAS staining in ≥ 50 villi per 
mouse (n ≥ 5 mice per gender). Scale bar: 25 μm. 
B. Representative examples of Olfm4 detection by in situ hybridization in small 
intestinal crypts of mice with the indicated genotypes. At least 50 crypts per mouse 
were counted (n ≥ 5 mice per gender). Scale bar: 10 μm. 
Results are presented as mean ± SEM. *** P < 0.001 (Student's t-test). 
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architectural changes were observed in both, male and female mice. 
Therefore, deletion of one Apc allele did not influence the morphological 
changes in the intestine caused by deletion of miR-34a/b/c. 
 
  
 
Figure 13. 
Determination of the width (left graph) and depth (middle graph) of small intestinal 
crypts. At least 200 crypts in the jejunum were analyzed. The length of the small 
intestine was determined in mice with the indicated genotypes (right graph, n ≥ 5 
mice per gender). Results are presented as mean ± SEM. *** P < 0.001 (Student's t-
test). 
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5.2 miR-34a/b/c loss enhances tumorigenesis in ApcMin/+ mice 
Notably, miR-34a/b/c-/-; ApcMin/+ mice showed signs of morbidity sooner 
and exhibited a shorter life-span than wild-type ApcMin/+ mice (Figure 14). In 
contrast, ApcMin/+ mice deficient for either the miR-34a or the miR-34b/c allele 
did not show a statistically significant change in life-span (Figure 14). 
 
 
 
When mice were sacrificed at the age of 18 weeks and the entire small 
intestinal tract was examined (Figure 15), miR-34a/b/c-/-; ApcMin/+ and, to a 
lesser extent, miR-34a-/-; ApcMin/+ knockout mice showed a significantly 
increased number of tumors when compared to ApcMin/+ mice (Figure 16A). 
Furthermore, the total tumor area in miR-34a/b/c-/-; ApcMin/+ mice was ~4 times 
larger than in wild-type ApcMin/+ mice (Figure 16B).  
 
Figure 14. 
Kaplan-Meier survival analysis of the indicated genotypes. Results were compared 
with a log-rank test. *** P < 0.001. 
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The frequency of large tumors (>6 mm2) was significantly higher when 
miR-34a/b/c, but not when only miR-34a or miR-34b/c genes had been 
deleted in ApcMin/+ mice (Figure 17).  
 
Figure 15. 
Representative images of resected small intestines. Scale bar: 1 cm. 
miR-34a
miR-34bc 
+/+
+/+
-/-
+/+
+/+
-/-
-/-
-/-
miR-34a
miR-34bc 
miR-34a
miR-34bc 
miR-34a
miR-34bc 
A  B  
 
 
 
 
Figure 16. 
Quantification of intestinal tumor number (A) and tumor area per mouse (B) (n ≥ 10 
mice per genotype). Results are presented as mean ± SEM. *** P < 0.001 (Student's 
t-test). 
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We also noted a significantly increased number of adenomas with high-
grade dysplasia in miR-34a/b/c-deficient ApcMin/+ mice, whereas the 
inactivation of either miR-34a or miR-34b/c alone did not have this effect 
(Figure 18).  
 
Figure 17. 
Graph showing the percentage of tumor size (surface area) distribution in ≥ 100 
tumors (n ≥ 10 mice per genotype). *** P < 0.001 (Chi-squared test). 
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Taken together, our findings show that the inactivation of miR-34a/b/c 
promotes intestinal tumor formation by increasing tumor initiation and 
enhancing the growth of tumors in ApcMin/+ mice. As the combined inactivation 
of miR-34a and miR-34b/c genes was necessary for these effects, these 
miRNAs may have overlapping functions and compensate each other. In 
addition, these results are in accordance with the combined epigenetic 
inactivation of miR-34a and miR-34b/c by DNA methylation, which has been 
detected in more than 75% of analyzed CRC samples [38]. In the subsequent 
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Figure 18. 
A. Tumor stage (low grade adenoma, high grade adenoma) of ≥ 66 intestinal tumors 
(n ≥ 10 mice per genotype). *** P < 0.001 (Chi-squared test). 
B. Representative images of low and high grade adenomas. Scale bar: 100 μm. 
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analyses, we therefore focused on studying mice with simultaneous deletion 
of miR-34a and miR-34b/c. 
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5.3 miR-34a/b/c loss affects proliferation, apoptosis and infiltration by 
bacteria and immune cells of adenomas 
Notably, tumors in miR-34a/b/c knockout ApcMin/+ mice showed a 
significant increase in proliferation and a significantly reduced rate of 
apoptosis (Figure 19). The frequency of stromal cells within the tumors was 
not affected by miR-34a/b/c deletion as determined by detection of Vimentin 
(Figure 20).  
 
 
Figure 19. 
IHC detection of Ki67 and cleaved-caspased-3 in adenomas from 18 weeks old 
ApcMin/+ mice with the indicated genotypes. (n = 7 mice per genotype). Results are 
presented as mean ± SEM. * P < 0.05, ** P < 0.01 (Student's t-test). Scale bar: 100 
μm. 
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Because it was recently shown that bacterial infiltration promotes 
tumorigenesis in ApcMin/+ mice [74], we asked whether miR-34a/b/c deletion 
affects the presence of bacteria in intestinal tumors. By detection of bacterial 
16S rRNA, we found that adenomas from miR-34a/b/c-/-; ApcMin/+ mice display 
extensive bacterial infiltration regardless of tumor size or tumor grade (Figure 
21). However, the adjacent normal intestinal epithelium of all mice analyzed 
here was devoid of bacteria. Therefore, miR-34a/b/c-deficient mice do not 
display a general intestinal barrier defect. 
 
Figure 20. 
Detection of Vimentin expression by immunohistochemistry in adenomas with the 
indicated genotypes. (n = 7 mice per genotype). Scale bar: 100 μm. 
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Unexpectedly, the frequency of immune cells, such as macrophages, T- 
and B-cell, was decreased in miR-34a/b/c-deficient adenomas (Figure 22). 
Therefore, the increased bacterial infiltration of adenomas may be due to a 
defect in the tumor-associated immune defense in miR-34a/b/c-deficient mice.  
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Figure 21. 
A. Fluorescence in situ hybridization (FISH) with a universal eubacterial probe 
(EUB338) in adenomas from 18 weeks old ApcMin/+ mice with the indicated 
genotypes. (n = 7 mice per genotype). Scale bar: 100 μm. 
B. Evaluation of EUB338 probe positive rate in different sizes (left panel) and 
different grades (right panel) adenomas. (n = 7 mice per genotype). *** P < 0.001 
(Fisher's exact test). 
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Figure 22. 
Quantification of infiltrated macrophages, B and T cells by F4/80, CD45R and CD3 
immuno-detection respectively in adenomas. (n ≥ 10 mice per genotype). Results 
are presented as mean ± SEM. *** P < 0.001 (Student's t-test). Scale bar: 100 μm. 
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5.4 Expression profiling of miR-34a/b/c-deficient adenomas 
To further illuminate the mechanisms by which miR-34a/b/c loss 
promotes intestinal tumorigenesis in ApcMin/+ mice we obtained mRNA 
expression profiles of adenomas from 18-weeks old miR-34a/b/c-deficient 
ApcMin/+ mice and wild-type ApcMin/+ mice. For each mouse (n=3 per genotype) 
RNAs derived from 3 different tumors were pooled, libraries were generated 
and subjected to RNA-Seq to obtain more than 35 million reads per library. 
Thereby we detected the up-regulation of 1773 mRNAs, when mRNAs with a 
|log2(fold change)| ≥ 0.6 and RPKM ≥ 0.25 in miR-34a/b/c-/-; ApcMin/+ mice 
versus wild-type ApcMin/+ mice were included (Figure 23). As expected, the 
percentage of mRNAs up-regulated in the miR-34a/b/c-deficient tumors was 
higher for mRNAs harboring miR-34a/b/c seed-matching sequences than for 
mRNAs lacking these (Figure 24). 
 
 
 
Figure 23. 
Results of NGS analysis represented as histogram showing changes in mRNA levels 
after miR-34a/b/c deletion. Transcriptionally regulated genes with a |log2(fold 
change)| ≥ 0.6 and RPKM ≥ 0.25 are highlighted as purple bars. Fold change 
denotes the ratio of mRNA expression values in tumors of miR-34a/b/c-/-; ApcMin/+ 
mice vs. miR-34a/b/c+/+; ApcMin/+ mice (n = 3 mice per genotype). 
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324 mRNAs were identified as differentially regulated due to miR-34a/b/c 
loss when the raw-count methods DESeq2 [75] and edgeR [76] were applied 
(Figure 25). After unsupervised clustering of these differentially expressed 
genes one of the miR-34a/b/c-deficient tumor samples showed a divergent 
expression profile, which was presumably due to biological variation (Figure 
26).  
 
 
Figure 24. 
Calculation of the percentage of mRNAs differentially regulated in miR-34a/b/c-
deficient vs. wild-type tumors in ApcMin/+ mice without (left graph) and with (right 
graph) miR-34a/b/c seed-matching sequences. *** P < 0.001. 
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Figure 25. 
Results of DESeq2 and edgeR analyses of the NGS results. 
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Next, we used Gene Ontology (GO) and KEGG pathway analyses to 
group the differentially expressed transcripts into functional classes. The GO 
analysis indicated that the up-regulated mRNAs are involved in cell adhesion, 
extracellular matrix and growth factor binding functions (Figure 27). The 
KEGG analysis showed that several pathways were significantly enriched, 
such as focal adhesion, ECM-receptor interaction, and pathways related to 
cancer (Figure 28).  
 
Figure 26. 
Heatmap of genes with significantly differential expression in tumors from mice with 
the indicated genotypes. Differential gene expression is shown according to the 
pseudocolor scale indicated on the right side. 
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On the contrary, both GO and KEGG analyses indicated that the down-
regulated genes are mainly involved in immune response functions (Figure 29 
and Figure 30).  
 
Figure 27. 
Top 5 Gene Ontology terms that were most significantly enriched among up-
regulated mRNAs of tumors from miR-34a/b/c-/-; ApcMin/+ mice. 
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Figure 28. 
Top 10 KEGG pathways that were most significantly enriched among up-regulated 
mRNAs of tumors from miR-34a/b/c-/-; ApcMin/+ mice. 
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A subsequent Gene Set Enrichment Analysis (GSEA) revealed that miR-
34a/b/c deletion results in gene expression signatures related to epithelial-
mesenchymal-transition (EMT), hypoxia, angiogenesis, inflammatory 
response, Kras signaling, and apical junction processes (Figure 31). 
 
Figure 29. 
Top 5 Gene Ontology terms that were most significantly enriched among down-
regulated mRNAs of tumors from miR-34a/b/c-/-; ApcMin/+ mice. 
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Figure 30. 
Top 10 KEGG pathways that were most significantly enriched among down-
regulated mRNAs of tumors from miR-34a/b/c-/-; ApcMin/+ mice. 
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Interestingly, the expression signatures of miR-34a/b/c-deficient adenomas 
also showed a significant overlap with signatures of intestinal stem cells (ISC) 
[77], Lgr5+ positive cells [78] and the GO Wnt signaling signature.  
 
 
In addition, several regulators of barrier function in IEC were also 
detected as down-regulated by NGS analysis in miR-34a/b/c-deficient 
adenomas (e.g. Muc1, Tff3 and Retnlb; fold change: -4.74, -1.44 and -3.34, 
respectively). The down-regulated mRNA expression of these barrier 
components was validated by qPCR (Figure 32A). Furthermore, we confirmed 
the decreased protein expression of MUC1 in miR-34a/b/c-deficient 
 
Figure 31. 
GSEA analysis of mRNA profiles from tumors of miR-34a/b/c-/-; ApcMin/+ mice vs. 
miR-34a/b/c+/+; ApcMin/+ mice. 
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adenomas by immunohistochemistry (Figure 32B). The repression of these 
barrier components may also contribute to the observed infiltration of bacteria 
into miR-34a/b/c-deficient adenomas. 
 
  
A  
 
 
B  
 
 
Figure 32. 
A. mRNA expression of barrier protein in adenomas from mice with the indicated 
genotypes (3 tumors per mouse) were determined by qPCR (n = 3 mice per 
genotype).  
B. Detection of MUC1 expression by immunohistochemistry (n ≥ 10 mice per 
genotype). Left panels: Representative examples of MUC1 detection in adenomas 
from mice with the indicated genotypes. Scale bar: 100 μm. Right panel: Evaluation 
of MUC1 expression using the H-score. 
Results in A and B are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 
0.001 (Student's t-test). 
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5.5 miR-34a/b/c loss enhances the formation of intestinal tumor 
organoids  
To obtain functional evidence for an enhanced stemness of adenoma 
cells with deletion of miR-34a/b/c we performed a tumor organoid formation 
assay. Indeed, an increased tumor organoid formation rate was observed for 
miR-34a/b/c-deficient adenoma derived cells when compared to those derived 
from miR-34a/b/c-proficient adenomas (Figure 33). 
 
  
 
Figure 33. 
Tumor organoid formation assay of adenomas (3 tumors per mice) from mice with 
the indicated genotypes (n = 2 mice per genotype). Scale bar: 200 μm. Results are 
presented as mean ± SEM. *** P < 0.001 (Student's t-test). 
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5.6 miR-34a/b/c deletion enhances intestinal Wnt signaling in ApcMin/+ 
mice 
Wnt/β-catenin signaling is critically involved in regulating the homeostasis 
and neoplastic transformation of the intestine. Since miR-34a/b/c-deficient 
adenomas showed a Wnt signaling signature (Figure 31) and the Wnt/β-
catenin pathway is directly regulated by miR-34a/b/c [54] and by APC, we 
determined whether the expression of β-catenin is also affected in the 
intestinal epithelial cells of miR-34a/b/c knockout mice. Interestingly, we 
detected an increased nuclear accumulation of β-catenin/CTNNB1 protein in 
normal crypts after miR-34a/b/c deletion in ApcMin/+ mice, but not in miR-
34a/b/c-deficient wild-type mice (Figure 34), indicating that miR-34a/b/c 
deficiency in the presence of hemizygous Apc allows the nuclear 
accumulation of β-catenin in untransformed cells including the stem cells 
located at the crypt base which represent the preferred cells of origin for 
intestinal adenomas [79]. Therefore, this effect of miR-34a/b/c loss may 
explain or at least contribute to the increased rate of tumor initiation in miR-
34a/b/c-deficient ApcMin/+ mice.  
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Figure 34. 
Detection of β-catenin localization. The number of nuclear β-catenin-positive cells 
was counted in ≥ 200 crypts (n = 5 mice per genotype). Scale bar: 20 μm. Results 
are presented as mean ± SEM. *** P < 0.001 (Student's t-test). 
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5.7 Validation of miR-34a/b/c target expression 
By bioinformatics analyses of the mRNA profiles obtained here we 
identified a set of 11 up-regulated mRNAs with miR-34 seed-matching sites in 
their 3’-UTR which may, at least in part, mediate the tumor suppressive 
function of miR-34a/b/c (Table 1 and Figure 35).  
 
Table 1. Subset of selected, up-regulated mRNAs with miR-34 seed-matching 
sequences 
Symbol Full Name Transcript ID 
Pdgfra platelet derived growth factor 
receptor, alpha polypeptide 
ENSMUST00000000476.9 
Pdgfrb platelet derived growth factor 
receptor, beta polypeptide 
ENSMUST00000025522.5 
Axl AXL receptor tyrosine kinase ENSMUST00000002677.5 
Wasf1 WAS protein family, member 1 ENSMUST00000105509.1 
Fgfr1 fibroblast growth factor receptor 1 ENSMUST00000179592.2 
Igf1 insulin-like growth factor 1 ENSMUST00000105300.3 
Stc1 stanniocalcin 1 ENSMUST00000014957.8 
Cacna2d2 calcium channel, voltage-dependent, 
alpha 2/delta subunit 2 
ENSMUST00000010210.7 
Col6a2 collagen, type VI, alpha 2 ENSMUST00000001181.7 
Col4a2 collagen, type IV, alpha 2 ENSMUST00000033899.8 
Inhbb inhibin beta-B ENSMUST00000038765.5 
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These mRNAs and a selected set of mRNAs with known pro-tumorigenic 
functions were analyzed by qPCR to exemplarily validate the NGS results 
(Figure 36). Several of these factors have already been characterized as 
direct miR-34 targets by others and us (Pdgfra [80], Pdgfrb [80], and Axl [56]). 
In addition, components of the Wnt pathway and EMT regulators were 
analyzed. Notably, all of the tested mRNAs were expressed at significantly 
higher levels in the tumors of miR-34a/b/c knockout ApcMin/+ mice. Therefore, 
our screen identified numerous additional miR-34a/b/c targets, which may be 
up-regulated in CRC and relevant for tumor progression. 
 
Figure 35. 
Positions of miR-34 seed-matching sequences (grey vertical bars) within selected 
mRNAs (left panel). 3’-UTR sequences of the miR-34 binding site of the selected 
mRNAs are given in 5’- to 3’- orientation (right panel). 
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Next, we performed an exemplary characterization of Wasf1 as a direct 
miR-34a/b/c target, since Wasf1 is known to regulate cancer-relevant 
processes [81]. A luciferase-based reporter containing the full-length 3’-UTR 
of the murine Wasf1 mRNA was significantly repressed by co-transfection of 
pre-miR-34a or pre-miR-34c (Figure 37). In addition, we detected a significant 
reduction of Wasf1 mRNA expression after ectopic expression of pri-miR-34a 
in SW620 CRC cells (Figure 38A). The WASF1 protein showed a delayed 
repression 72 hours after activation of the pri-miR-34a allele which may be 
due to an unusually stable WASF1 protein (Figure 38B).  
 
Figure 36. 
mRNA expression of selected genes in tumors from mice with the indicated 
genotypes (3 tumors per mouse) were determined by qPCR (n = 3 mice per 
genotype). Results are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 
0.001 (Student's t-test). 
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Consistent with being a miR-34a/b/c target, the WASF1 protein showed 
increased expression in three out of four tumors isolated from miR-34a/b/c 
 
Figure 37. 
Dual reporter assay in H1299 cells co-transfected with pre-miR-34a mimics, pre-
miR-34c mimics or control oligonucleotides and Wasf1 3’-UTR-reporter constructs (n 
= 3). Results are presented as mean ± SD. * P < 0.05 (Student's t-test). 
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Figure 38. 
A. Detection of Wasf1 mRNA by qPCR after addition of DOX for the indicated 
periods to SW620/pRTR-pri-miR-34a cells (n = 3). Results are presented as mean ± 
SD. * P < 0.05 (Student's t-test). 
B. Western blot analysis of WASF1 after activation of ectopic pri-miR-34a expression 
for the indicated periods in SW620/pRTR-pri-miR-34a cells (n = 3). 
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knockout ApcMin/+ mice, when compared to miR-34a/b/c-proficient tumors 
(Figure 39). Taken together, these results show that Wasf1 is a direct target of 
miR-34a/b/c.  
 
  
 
Figure 39. 
Western blot analysis of WASF1 expression in tumors from miR-34a/b/c-/-; ApcMin/+ 
mice or miR-34a/b/c+/+; ApcMin/+ mice (n = 4 mice per genotype). 
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5.8 Increased expression of miR-34a/b/c targets in human CRCs is 
associated with poor survival 
In order to determine whether the miR-34 targets described above are 
also clinically relevant, we analyzed their expression within the expression 
profiles of 460 human colorectal adenocarcinomas deposited in The Cancer 
Genome Atlas (TCGA) database [71]. Interestingly, INHBB, PDGFRB, STC1 
and COL4A2 showed a significantly elevated expression in primary CRCs 
(Figure 40).  
 
 
Furthermore, a significantly increased expression of INHBB, AXL, FGFR1 
and PDGFRB was detected in primary CRCs from patients with nodal status 
N2 when compared to samples from patients with lower nodal status (Figure 
41). Except for AXL, a significantly increased expression of these mRNAs was 
associated with an increased tumor stage (Figure 42).  
 
Figure 40. 
Expression of selected miR-34 targets in tumor and matched normal tissue in the 
TCGA collection of COAD (n = 41 patients). Results are presented as mean ± SEM. 
* P < 0.05, ** P < 0.01, *** P < 0.001 (Paired Student's t-test). 
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In addition, increased expression of INHBB and AXL in primary CRCs 
was significantly associated with decreased patient survival (Table 2 and 
Figure 43). Elevated expression of COL4A2, WASF1, STC1 and PDGFRB 
was also associated with poor survival, although not significantly (Figure 43). 
Since poor survival is mostly due to metastatic spread, these results suggest 
that the elevated expression of these mRNAs, which may be due to loss of 
miR-34a/b/c, promotes metastasis. 
 
Figure 41. 
Correlation of selected mRNA expression in tumor with nodal status (n = 460 
patients). Results are presented as mean ± SEM. * P < 0.05, ** P < 0.01 (Student's t-
test). 
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Figure 42. 
Correlation of selected mRNA expression with tumor stage (n = 460 patients). 
Results are presented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001 
(Student's t-test). 
lo
g
2
(N
_
R
S
E
M
+
1
)
10
0
15
5
T1 T2 T3 T4
FGFR1
T
1
T
2
T
3
T
4
0
5
1 0
1 5
*
*
T
1
T
2
T
3
T
4
0
5
1 0
1 5
lo
g
2
(N
_
R
S
E
M
+
1
)
T1 T2 T3 T4
PDGFRB
**
**
T
1
T
2
T
3
T
4
0
5
1 0
1 5
lo
g
2
(N
_
R
S
E
M
+
1
)
0
0
5
5
T1 T2 T3 T4
INHBB
*
***
*
**
5. Results 
80 
 
 
Table 2. Univariate and age/gender/tumor grade-adjusted Cox proportional 
hazard analysis of selected up-regulated mRNAs with miR-34 seed-
matching sequences and overall-survival in the TCGA COAD cohort 
mRNA Univariate 
 Age/gender/tumor grade-
adjusted 
 HR (95% CI) P  HR (95% CI) P 
Col4a2 1.211 (0.952-1.539) 0.118  1.170 (0.917-1.494) 0.207 
Fgfr1 1.101 (0.866-1.399) 0.434  1.048 (0.823-1.334) 0.703 
Axl 1.276 (1.014-1.607) 0.038  1.269 (1.007-1.600) 0.044 
Stc1 1.199 (0.944-1.523) 0.136  1.133 (0.887-1.447) 0.318 
Pdgfrb 1.160 (0.912-1.474) 0.226  1.150 (0.901-1.469) 0.261 
Cacna2d2 0.868 (0.680-1.109) 0.258  0.883 (0.689-1.131) 0.324 
Igf1 0.990 (0.777-1.261) 0.933  1.040 (0.813-1.331) 0.756 
Col6a2 1.077 (0.845-1.373) 0.547  1.079 (0.844-1.378) 0.545 
Pdgfra 0.859 (0.679-1.087) 0.206  0.922 (0.724-1.175) 0.512 
Inhbb 1.486 (1.152-1.916) 0.002  1.338 (1.028-1.742) 0.030 
Wasf1 1.200 (0.945-1.522) 0.134  1.125 (0.884-1.432) 0.338 
  HR: hazard ratio, CI: confidence interval, COAD: colon adenocarcinoma 
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Finally, we compiled the regulations identified here and combined them 
with previously published results on miR-34a/b/c-regulated pathways in a 
summarizing model shown in Figure 44. Notably, several of the miR-34 
targets displaying elevated expression after miR-34a/b/c deletion are involved 
in transmembrane signal transductions, which also activate the Wnt signaling 
pathway by inhibition of GSK-3β. Taken together, miR-34a/b/c presumably 
suppresses intestinal tumorigenesis caused by loss of Apc by down-regulating 
the expression of a large number of pro-tumorigenic factors. In case miR-
34a/b/c expression is lost or silenced during tumor progression these 
pathways may be further activated and thereby contribute to CRC progression.  
 
Figure 43. 
Kaplan-Meier analysis of overall survival (n = 306 patients). Results were compared 
with a log-rank test. 
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Figure 44. 
Summarizing model of regulations and signal transduction events activated by 
deletion of miR-34a/b/c in ApcMin/+ mice identified in this study. In addition, selected 
previously published (in red) or predicted (in purple) miR-34a/b/c target genes, as 
well as WNT-regulated factors (in cyan) are depicted. 
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6. Discussion 
We generated transgenic mice with deletion of miR-34a/b/c alleles to 
examine the consequences of miR-34a/b/c inactivation for normal 
development and tumorigenesis. In previous studies, Concepcion et al. 
reported that deletion of miR-34a/b/c is compatible with normal development 
in mice and does not increase spontaneous carcinogenesis [42]. Our results 
confirmed their findings, since miR-34a/b/c-deficient mice did not show any 
significant changes in lifespan. Interestingly, miR-34a/b/c and miR-449a/b/c 
constitute a superfamily of miRNAs and contain the same “seed region”. 
Therefore, certain miR-34 functions may be compensated by other miRNAs, 
such as miR-449, which share a similar seed-matching sequence. In line with 
this assumption, mice deficient for miR-34a/b/c and miR-449a/b/c display 
impaired mucociliary clearance and postnatal mortality, infertility and 
respiratory dysfunction [45]. However, it should be noted that miR-449a/b/c 
are not induced by p53 and seem to function as oncogenes, as they are 
induced by E2F transcription factors.  
Here we observed changes in the intestinal architecture in miR-34a/b/c-
deficient mice indicate that miR-34a/b/c have functions in the homeostasis of 
intestinal epithelial cells. miR-34 may achieve this via some of its target 
mRNAs, such as Pdgfra and Klf4, which encode proteins that are known to be 
involved in the development of the intestine and differentiation of intestinal 
epithelial cells. Interestingly, Pdgfra-deficient mice show fewer and deformed 
villi [82], and mice with a Klf4 deletion show a 90% reduction of Goblet cells in 
the colon [83]. Furthermore, Sox9-deficient mice have decreased numbers of 
Paneth cells [84].  
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As we expected, the alterations of the small intestinal architecture were 
retained in ApcMin/+ mice after miR-34a/b/c loss. Notably, an increased tumor 
burden and size, and decreased survival were found in miR-34a/b/c deletion 
ApcMin/+ mice. The increase in the pool of intestinal stem cells (ISC) in the 
miR-34a/b/c-deficient mice observed here may underlie the increased rate of 
tumor formation in ApcMin/+ mice, since ISC were shown to serve as efficient 
tumor initiating cells during intestinal tumorigenesis [79]. Paneth cells provide 
a niche for ISCs and communicate with these via multiple signaling pathways, 
among them the Delta/NOTCH and Wnt/APC/-catenin pathways, which are 
under negative control by miR-34a/b/c [34,54]: e.g. several key components 
of the Wnt signaling pathway are miR-34a/b/c targets (WNT1, WNT3, LRP6, 
LEF1, and β-catenin [54,56]. Moreover, GSK-3β, which phosphorylates β-
catenin and thereby leads to its poly-ubiquitination and proteasomal 
degradation, is inhibited by the PKB/AKT and PI3K pathways, which are also 
under control of miR-34a/b/c. Therefore, the concerted deregulation of the 
NOTCH and WNT pathways caused by the loss of miR-34a/b/c is a likely 
cause for the increased number of Paneth and stem cells. In support of this 
scenario, we also noticed an increased tumor organoid formation rate in miR-
34a/b/c-/-; ApcMin/+ adenomas as well as an increased accumulation of nuclear 
β-catenin in the untransformed, epithelial cells of intestinal crypts in miR-
34a/b/c-deficient ApcMin/+ mice. In addition, a recent study suggests that 
activation of the Wnt/β-catenin pathway correlates with T cell exclusion [85]. 
Therefore, miR-34 may regulate immune responses through Wnt signaling. In 
addition, the expression of barrier proteins was decreased in miR-34a/b/c-/-; 
ApcMin/+ mice (e.g. Muc1, Tff3, and Retnlb). In combination with the decreased 
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presence of immune cells, these effects of miR-34a/b/c loss may contribute, 
at least in part, to the increased bacterial infiltration observed in miR-34a/b/c-/-; 
ApcMin/+ adenomas. 
In addition, utilizing whole transcriptomic analysis and subsequent KEGG, 
GO, and GSEA pathway analysis, we found that the deletion of miR-34a/b/c in 
adenomas leads to the up-regulation of previously described miR-34a/b/c 
target mRNAs, such as Pdgfra, Pdgfrb, and Axl, which are known to enhance 
CRC formation [86]. Furthermore, a set of novel, putative miR-34a/b/c target 
mRNAs (Wasf1, Fgfr1, Igf1, Stc1, Cacna2d2, Col6a2, Col4a2, and Inhbb), 
which were reported to be involved in tumorigenesis [81,87-92], was up-
regulated in miR-34a/b/c-deficient adenomas. The factors encoded by these 
genes form complex signaling and functional networks (Figure 44): PDGFRA, 
PDGFRB, FGFR1, AXL and IGF1, which are either ligands or receptors of the 
tyrosine kinase family, activate the PI3K and MAPK signaling pathway, and 
thereby promote cell growth, survival, EMT and metastasis [93,88,87,94,95]. 
Notably, CACNA2D2, a voltage-dependent calcium channel, deregulates 
calcium homeostasis when ectopically expressed [90]. The resulting calcium 
release may induce the activation of PKB/AKT and RAS, which are the 
mediators of the PI3K and MAPK pathways, and eventually promote cell 
proliferation and angiogenesis [90]. AXL kinase, a receptor tyrosine kinases 
(RTK) family member, transduces its signal through PI3K pathway and 
regulates cell survival, aggregation, and proangiogenic behavior [96-98]. 
INHBB assembles into Activins, which are critical modulators of growth and 
survival [99,92]. Components of the extracellular matrix (ECM), are commonly 
deregulated during tumor progression [100] and were found to be up-
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regulated putative miR-34a/b/c targets in this study: the collagen COL4A2 is a 
major structural protein of the basement membrane [101] and COL6A2 has an 
anchoring function [102]. Both collagens stimulate integrin signaling and are 
involved in cell growth, angiogenesis, and tumor metastasis [91]. WASF1, a 
new miR-34a/b/c target characterized here, mediates actin polymerization, 
lamellipodia formation and plays a critical role in cancer cell migration and 
invasion [103,104,81]. STC1 is an endocrine regulator of calcium and 
phosphate homeostasis which promotes cell proliferation and inhibits 
apoptosis through CCND1 and CDK2/4 [105].  
Taken together, miR-34a/b/c presumably act as global regulators to fine 
tune multiple cellular functions, which are necessary for the homeostasis of 
intestinal epithelia. Since miR-34a has been shown to form bimodal switches 
with at least some of its targets [34], the epigenetic silencing of miR-34a/b/c 
during CRC progression may have significant effects on the regulation of 
these signaling and expression networks which ultimately promote intestinal 
tumorigenesis. miR-34a/b/c have a multitude of targets in intestinal epithelial 
and colon cancer cells as shown here and in previous studies [19]. Therefore, 
it seems plausible that the effects of miR-34a/b/c loss are mediated by the 
combined activity of multiple up-regulated targets and not by one or a few 
targets.  
Our results suggest that a subset of the direct targets of miR-34a/b/c may 
significantly contribute to human colorectal tumorigenesis since their elevated 
expression was associated with poor clinical outcomes of CRC patients. 
Interestingly, decreased miR-34a expression, caused by CpG-methylation of 
its promoter, in combination with increased β-catenin expression are more 
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significantly associated with liver metastases of CRC than their single 
deregulation [39]. In the future, the detection of miR-34a/b/c silencing and up-
regulation of its targets in primary CRC samples may be used for predictive 
and prognostic purposes. Furthermore, our results suggest that miR-34 
mimetics may be used to target multiple key pathways simultaneously and 
could thereby potentially prevent the emergence of resistance caused by 
mutations of single pathways. Therefore, miR-34a/b/c replacement therapy 
may represent a potential option for the treatment of CRC. 
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7. Summary 
The p53-inducible miR-34a and miR-34b/c genes are frequently silenced 
in colorectal cancer (CRC). To address the in vivo relevance of miR-34a/b/c 
function for suppression of intestinal tumor formation, we generated ApcMin/+ 
mice with deletions of the miR-34a and/or miR-34b/c genes separately or in 
combination. Combined deletion of miR-34a/b/c increased the number of 
intestinal stem cells as well as Paneth and Goblet cells, resulting in enlarged 
intestinal crypts. miR-34a/b/c-deficient ApcMin/+ mice displayed an increased 
tumor burden and grade, and decreased survival. miR-34a/b/c-deficient 
adenomas showed elevated proliferation, decreased apoptosis and displayed 
pronounced bacterial infiltration, which may be due to an observed decrease 
in infiltrating immune cells and down-regulation of barrier proteins. mRNAs 
induced in miR-34a/b/c-deficient tumors were enriched for miR-34a/b/c seed-
matching sites and for mRNAs encoding proteins related to epithelial-
mesenchymal transition (EMT), stemness and Wnt signaling. Accordingly, 
cells explanted from miR-34a/b/c-deficient adenomas formed tumor organoids 
at an increased rate. Several up-regulated miR-34 targets displayed elevated 
expression in primary human CRCs that was associated with lymph-node 
metastases (INHBB, AXL, FGFR1, PDFGRB) and up-regulation of INHBB and 
AXL in primary CRC was associated with poor patient survival. In conclusion, 
these results show that miR-34a/b/c suppress tumor formation caused by loss 
of Apc and control intestinal stem cell and secretory cell homeostasis by 
down-regulation of multiple target mRNAs.   
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8. Zusammenfassung 
Beim Kolorektalkarzinom werden die p53-induzierbaren miR-34a und 
miR-34b/c Gene häufig durch DNA-Methylierung inaktiviert. Um die in vivo 
Relevanz der miR-34a/b/c Funktion für die Unterdrückung der Bildung von 
intestinalen Tumoren zu untersuchen, haben wir ApcMin/+ Mäuse mit 
getrennten oder kombinierten Deletionen der miR-34a oder miR-34b/c Gene 
generiert. Die kombinierte Deletion von miR-34a/b/c erhöhte die Anzahl der 
Darmstammzellen sowie von Paneth- und Becherzellen, was zu vergrößerten 
Darmkrypten führte. miR-34a/b/c-defiziente ApcMin/+ Mäuse zeigten vermehrte 
Tumorbildung, einen erhöhten Malignitätsgrad und ein vermindertes 
Überleben. Zudem wiesen miR-34a/b/c-defiziente Adenome eine erhöhte 
Proliferation und verminderte Apoptose, sowie eine ausgeprägte bakterielle 
Infiltration auf. Diese könnte durch die beobachtete Abnahme der 
infiltrierenden Immunzellen und die verminderte Expression von Barriere-
Proteinen erklärt werden. mRNAs welche in miR-34a/b/c-defizienten Tumoren 
verstärkt gebildet wurden, waren für miR-34a/b/c-Seed-Matching-Motive 
angereichert und für mRNAs, die Proteine kodieren, die mit epithelial-
mesenchymalen Übergang (EMT), Stammzelligkeit und dem Wnt-Signalweg 
zusammenhängen. Dementsprechend bildeten Zellen, die aus miR-34a/b/c-
defizienten Adenomen explantiert wurden, Tumor-Organoide mit einer 
erhöhten Rate. Mehrere hochregulierte miR-34 Targets zeigten eine erhöhte 
Expression in primären menschlichen Kolorektalkarzinomen, die mit 
Lymphknotenmetastasen (INHBB, AXL, FGFR1, PDFGRB) assoziiert waren, 
und die Hochregulierung von INHBB und AXL in primären 
Kolorektalkarzinomen war mit geringeren Überleben der Patienten assoziiert. 
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Zusammenfassend zeigen diese Ergebnisse, dass miR-34a/b/c die intestinale 
Tumorbildung, die durch den Verlust von Apc verursacht wird, unterdrückt und 
die Homöostase von intestinalen Stammzellen und sekretorischen Zellen 
durch die Inhibition mehrerer Ziel-mRNAs kontrolliert. 
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